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Abstract
The nitric oxide (NO) synthase family of enzymes generate NO from L-arginine, which acts as a biologic effector molecule
in a broad number of settings. This report summarizes some of the current information regarding NO synthase structure-
function, reaction mechanism, control of catalysis, and protein interactions. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Nitric oxide (NO) is synthesized in animals and
simpler life forms through sequential oxidation of
L-arginine (L-arg) (reviewed in [1,2]) (Fig. 1). Biolog-
ical hydroxylation of a terminal L-arg nitrogen was
unknown prior to the discovery of the L-arg-to-NO
pathway in 1987, although hydroxylation at other
positions in L-arg had been demonstrated. The path-
way grew to prominence once it was realized that
NO is responsible for the tumor cytostatic activity
of macrophages [3] and was the endogenous vaso-
relaxant produced by blood vessels in human endo-
thelium (reviewed in [4]). Subsequently this NO bio-
synthetic pathway has been shown or implied to
function in many physiologic and pathologic settings.
NO synthesis is catalyzed by the NO synthases
(NOSs), which all utilize NADPH and O2 as cosub-
strates. Three NOS isoforms have evolved to func-
tion in animals, and each gene is located on a di¡er-
ent chromosome [5]. Although alternatively spliced
NOSs are sometimes expressed they are often missing
structural elements critical for full function [6,7].
Two of three NOS are constitutively expressed in
cells, and they synthesize NO in response to in-
creased Ca2 or in some cases in response to Ca2-
independent stimuli like shear stress [8]. These NOSs
function in signal transduction cascades by linking
temporal changes in Ca2 level to NO production,
which serves as an activator of soluble guanylate
cyclase [9]. The constitutive enzymes are designated
nNOS and eNOS (or NOS I and III, respectively),
after the cell types in which they were originally dis-
covered (rat neurons and bovine endothelial cells).
An inducible NOS (iNOS or NOS II) is constitu-
tively expressed only in select tissues like lung
epithelium [10] and is more typically synthesized
in response to in£ammatory or proin£ammatory
mediators [11,12]. Expression of iNOS may be bene-
¢cial in host defense or in modulating the immune
response, but its expression is also linked to a num-
ber of in£ammatory diseases (reviewed in [3,12,13]).
Mouse strains in which individual or multiple NOS
genes have been knocked out are being characterized
[13,14]. Achieving selective pharmacologic control of
the NOSs should help clarify how each functions in
human health and disease.
This article summarizes recent work on NOS en-
zymology, including NOS structure, function, and
catalytic control. In most cases, work has been
done using the mouse iNOS, bovine eNOS and rat
nNOS isoforms, and readers are encouraged to con-
sult the original papers for species information. For
information on NOS expression, or on the biology,
pharmacology, physiology, or pathology of NO, the
reader is directed to recent papers or reviews [15^18].
2. NOS structure-function
2.1. Background
Each NOS polypeptide is comprised of an N-ter-
minal oxygenase domain and a C-terminal reductase
domain, with an approximate 30 amino acid recog-
nition sequence for the Ca2 binding protein cal-
modulin (CaM) located between the two domains
(reviewed in [19^21]) (Fig. 2). The NOS oxygenase
domains share a core region that starts at about pro-
line 76 in mouse iNOS and extends approx. 500 res-
idues to the CaM binding sequence. The core region
binds heme, tetrahydrobiopterin (H4B), L-arg, and
forms the active site where NO synthesis takes place.
The N-terminal region that is located upstream from
the oxygenase core varies in length among the NOS,
participates in cellular targeting, and in some cases
may a¡ect NOS structure or catalysis. The C-termi-
nal reductase domains start at the end of the CaM
binding sequences and extend 570^625 residues. The
reductase domains bind FMN, FAD, and NADPH.
During NO synthesis the reductase £avins acquire
electrons from NADPH and transfer them to the
heme iron, which permits it to bind and activate
O2 and catalyze NO synthesis [19^21]. In eNOS
and nNOS, the £avin-to-heme electron transfer is
triggered by CaM binding, which explains how
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Ca2 and CaM can regulate NO synthesis by these
constitutive NOSs. In mouse iNOS CaM binding is
essentially irreversible [22], consistent with iNOS
being continuously active once assembled. When ex-
pressed in bacteria, eNOS and nNOS fold properly
without CaM [23^25], whereas iNOS does not
[26,27], suggesting CaM binding helps fold the
iNOS polypeptide.
All three NOS are homodimers in their active
forms [19^21]. Only the oxygenase domains of each
NOS appear necessary to form the dimer [28^30],
although some reports suggest that the reductase do-
mains or CaM binding site may help regulate the
interaction in eNOS [31,32,66]. In iNOS dimerization
is promoted by heme incorporation, H4B and L-arg
[21], and occurs in a two stage process (Fig. 3) in
which a functional reductase domain forms ¢rst, fol-
lowed by heme incorporation, and dimerization of
monomers with stable incorporation of H4B. In
eNOS and nNOS, heme incorporation is essential
for their dimer assembly but H4B may not be needed
[25,33,34,66], although H4B can stabilize the nNOS
dimer once formed [132]. A study which investigated
the ability of protoporphyrin IX containing various
metals to incorporate into heme-free nNOS mono-
mer suggests that formation of a metal-thiolate
bond is a critical step that alters nNOS conformation
and enables the monomers to dimerize [33].
The oxygenase and reductase domains of each
NOS have been expressed separately in a number
of di¡erent cell systems and in general retain their
individual composition, structure, and catalytic prop-
erties [28^30,35,53,63]. Crystal structures of an N-
terminally deleted monomeric iNOS oxygenase [36]
and a dimeric iNOS oxygenase [37] were recently
solved and information from these structures is inte-
grated into some of the following sections.
2.2. NOS reductase domains
The NOS reductase domain sequences are at least
50% homologous with other FMN- and FAD-con-
taining reductases such as cytochrome P-450 reduc-
tase [38,46], and data obtained thus far suggest the
NOS reductase domains conserve the key features of
this class of enzymes. When expressed individually or
as part of the full enzyme the NOS reductase do-
mains can directly transfer electrons from NADPH
to arti¢cial acceptors such as cytochrome c or ferri-
cyanide at high rates [28,34,35,39]. Oxygen, however,
is reduced relatively slowly by the reductase
[34,35,40,64,133,134]. NOS reductases stabilize their
one-electron reduced £avin semiquinone forms to
varying degrees [29,35,41,42] and can accept at least
three electrons from NADPH [29,35]. Thus, it is
likely that their two- and three-electron reduced
forms are utilized to transfer electrons to the heme
during NO synthesis. NADPH-dependent £avin re-
duction occurs rapidly in iNOS and nNOS [43,44],
but has not been measured in eNOS. The eNOS also
displays a smaller fold increase in cytochrome c re-
duction in response to CaM [28,34,39,41,45], and
NO synthesis in eNOS may actually be limited by
the rate at which the reductase can transfer electrons
to the oxygenase domain heme iron [45]. The crystal
structure of the homologous dual-£avin enzyme
NADPH cytochrome P-450 reductase [46] predicts
a tri-domain structure for the NOS reductases, con-
sisting of fused FMN, FAD, and NADPH binding
subdomains arranged in series, with the C-terminal
FMN domain capable of interacting with the NOS
oxygenase domain for electron transfer during NO
synthesis. Some critical NADPH binding residues
in the extreme C-terminal end of the iNOS reductase
have been identi¢ed by mutagenesis [65]. The isolated
eNOS and iNOS reductases can support varying de-
grees of NO synthesis when mixed with their respec-
tive oxygenase domains [28,47], although the rates
are less than those observed for intact full-length
enzymes.
2.3. NOS oxygenase domains
In contrast to the modular structure predicted for
the NOS reductase domains, the core structure of the
iNOS oxygenase is formed by one continuous fold
made up of several overlapping or winged L sheets, a
feature likely shared among all three NOS [36]. Thus,
the structural elements responsible for binding L-arg,
H4B, and heme are located throughout the oxygen-
ase domain, rather than being arranged in a linear
series of subdomains along the polypeptide sequence.
The core structure of winged L sheets distinguishes
NOS from the cytochrome P-450 superfamily, whose
folds are mainly comprised of helical elements
[48,49]. A comparison of iNOS oxygenase monomer
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and dimer structures reveals that dimerization may
recruit peripheral loop and helical elements from
both the N- and C-terminal ends of the core oxygen-
ase domain into a central region that forms an ex-
tensive dimer interface, H4B binding site, and sub-
strate channel [37]. The oxygenase winged L sheet
structure is not signi¢cantly altered by dimerization.
Residues from opposite ends of two interacting oxy-
genase peptides are brought together and interact at
the dimer interface. Molecular movements associated
with dimerization also expose a heme edge on the
solvent-accessible convex side of the protein. The
surface residues in this area are highly conserved
among the NOS and are predicted to form a docking
site for electron transfer from the reductase domain
[37]. Residues that participate in L-arg and H4B bind-
ing are linked through an integrated network of H-
bonding, likely explaining why these molecules bind
in a cooperative manner to the NOS [34,50,51].
Although all mutational studies published to this
point were done without the aid of the crystal struc-
tures, they can now serve to check functions implied
by the recent structural data. For example, in the
mouse iNOS oxygenase dimer the N-terminal seg-
ments Q77-S105 of each subunit form hairpin loop
structures (Fig. 2) that may reach out to interact with
distinct structural elements on the adjacent oxygen-
ase [37]. Progressive deletion analysis in iNOS,
eNOS, and nNOS had already demonstrated the im-
portance of the N-terminal region in maintaining
dimer stability or for binding L-arg and H4B
[30,52,53]. Deletions preceding the core oxygenase
had little or no e¡ect on structure and catalysis. De-
letions up to 40 residues into the core region pro-
gressively prevented dimerization and binding or re-
sponse to L-arg and H4B without a¡ecting heme
content or properties, consistent with the hairpin
loop functioning in dimer stability. Because the N-
terminal hairpin loop sequence is only moderately
conserved among the NOS, it can potentially impart
characteristics unique to each isoform. For example,
point mutagenesis of conserved residues in the anal-
ogous hairpin loop region of nNOS suggest it may
also govern heme function in that isoform [54]. In
addition, deletion of the approx. 220 residue N-ter-
minal leader sequence unique to nNOS lowered its
activity by two-thirds [6], although in a di¡erent
study similar deletion did not a¡ect nNOS heme
incorporation or a⁄nity toward H4B and L-arg
[53].
Crystal structures of the mouse iNOS oxygenase
domain [36,37] also reveal how L-arg and analogs
bind within the active site. A side chain carboxyl
from a conserved glutamate (E371 in iNOS) hydro-
gen bonds with two guanidino nitrogens of L-arg,
positioning the third terminal L-arg nitrogen over
the heme iron for potential hydroxylation [37]. Mu-
tagenesis of this conserved glutamate caused an ab-
solute and speci¢c loss of L-arg binding in bovine
eNOS and mouse iNOS [55,56]. Several other oxy-
genase point mutations a¡ected both L-arg and H4B
binding, and in some cases also inhibited dimeriza-
tion [55]. Such mixed phenotypes likely re£ect the
integration of binding sites for these molecules within
the subunit interface [37]. In two cases relatively con-
servative point mutations (G450A, A453I) com-
pletely prevented iNOS subunit dimerization and
consequent L-arg or H4B binding [57]. These residues
provide backbone interactions that insure proper
alignment between the C and N termini of adjacent
oxygenase polypeptides in the iNOS dimer [37].
There are two identical H4B binding sites in the
iNOS dimer [37], consistent with biochemical studies
that indicate maximal activity is achieved when each
subunit contains one H4B [58,59]. Surprisingly, resi-
dues that make up a given H4B binding site are con-
tributed from both polypeptides in the dimer [37].
This helps explain why H4B binding and subunit
dimerization are associated in iNOS [21]. It also pre-
dicts that both cis and trans acting mutations will be
possible, i.e., mutation of residues that a¡ect H4B
binding in either the same or adjacent subunit.
2.4. Thiol mutagenesis
Eight cysteines are conserved within the core oxy-
genase domains of the NOS. Mutagenesis and se-
quence analysis correctly predicted the heme-binding
cysteine in each NOS [29,60,61,67,108]. The crystal
structures suggest that one core oxygenase domain
cysteine can engage in disul¢de bond formation
(C109 in mouse iNOS), which forms a disul¢de
with C109 located on the adjacent subunit of the
dimer [37]. Although the functional consequences
are unknown, disul¢de bond formation at C109
could reversibly modify iNOS function in response
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to oxidant stress. Mutagenesis of C109 to Ala in
iNOS and mutagenesis of the analogous C99 in bo-
vine eNOS did not negate dimerization or NO syn-
thesis, but did decrease mutant a⁄nity toward H4B
[30,62]. Individual mutagenesis of other conserved
oxygenase domain cysteines to Ala had little or no
e¡ect on NOS structure and catalysis [63,57,67,108]
(Table 1). Conserved thiols within the NOS reductase
domains have not been studied by mutagenesis.
2.5. NOS domain interactions
Oxygenase-oxygenase or oxygenase-reductase do-
main interactions have been examined using yeast
two-hybrid analysis [66], nNOS-eNOS-iNOS chime-
ras in which reductase domains have been swapped
[45], and iNOS heterodimers formed either by co-
expressing dissimilar NOS polypeptides or NOS chi-
meras in cells [31,61,68] or by combining dissimilar
puri¢ed iNOS polypeptides in vitro [69,71]. The NOS
reductase-oxygenase chimera work showed that a
given reductase could still transfer electrons to oxy-
genase domains from other NOS isoforms and sup-
port NO synthesis. Furthermore, these NOS chime-
ras displayed a rate of NO synthesis characteristic of
the reductase they contained [45]. This was particu-
larly striking for the eNOS reductase-nNOS oxygen-
ase chimera, whose rate of NO synthesis was slowed
considerably compared to native nNOS. The authors
proposed that electron transfer from the eNOS re-
ductase is slow enough to become rate-limiting for
NO synthesis. In the heterodimer co-expression stud-
ies, iNOS polypeptides containing a mutation which
rendered them inactive in a homodimeric setting
often could dimerize with a wild-type iNOS mono-
mer or with an iNOS monomer containing a dissim-
ilar mutation [61]. This usually resulted in an active
heterodimer regarding NO synthesis, but in some
cases an inactive heterodimer was formed. For exam-
ple, the G450A mouse iNOS mutant positively com-
plimented an iNOS mutant expressing a NADPH
binding defect, while the C194A heme-binding mu-
tant did not. This led to the conclusion that two
hemes need be incorporated for an iNOS dimer to
generate NO.
Characterization of a puri¢ed iNOS heterodimer
comprised of one full-length and one oxygenase do-
main subunit showed that the single reductase do-
main could transfer electrons to only one of the
two hemes, and this was su⁄cient to support a nor-
mal rate of catalysis by that heme [69]. This result is
consistent with nNOS biochemical studies [59,70],
and the iNOS crystal structures [37] which all indi-
cate that each heme functions independently in a
NOS dimer. Recently, similar iNOS heterodimers
that contain an E371A L-arg binding mutation in
either subunit were used to determine the pathway
of heme reduction [71]. This work revealed that elec-
trons transfer only between reductase and oxygenase
domains located on adjacent subunits of the dimer
(Fig. 4). This helps explain why iNOS dimerization is
critical for NO synthesis, has implications for CaM
function, and links evolution of iNOS quaternary
structure to domain function. It is conceivable that
eNOS and nNOS dimers engage in a similar cross-
subunit interaction during electron transfer to their
hemes.
2.6. Calmodulin
CaM plays a critical role in activating NOS be-
cause its binding triggers electron transfer to the
heme [72]. Although the exact mechanism for CaM’s
action is still unknown, some information is avail-
able. CaM binding to nNOS alters the conformation
of the reductase domain [35,73,74], increases the rate
of electron transfer into the £avins [35,44], and in-
creases the rate at which the reductase can transfer
electrons to acceptors such as cytochrome c or ferri-
cyanide [20,23,24,44]. Most of these changes also oc-
cur when CaM binds to eNOS, but to a much small-
er extent [28,34,39,41,75]. Work with an isolated
nNOS reductase domain that contains an N-terminal
CaM binding site show that CaM activates the re-
ductase domain independent of the oxygenase do-
main [29,35,44,64]. Oxygenase domain properties
and reactivity are unchanged or are a¡ected to a
much lesser extent upon CaM binding to the full-
length enzymes [76,77]. Although this indicates that
CaM must activate NO synthesis by in£uencing the
reductase domain, which changes in domain struc-
ture and activity enable heme reduction during NO
synthesis remain to be de¢ned.
The CaM-nNOS interaction has been investigated
using CaM mutants in which the Ca2 binding site in
each of CaM’s four domains was individually abol-
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ished [78], and using chimeras constructed from CaM
and the homologous Ca2 binding protein cardiac
troponin c [44,79,80], which on its own does not
activate nNOS. These studies show that structural
integrity of CaM domains 1, 3, and possibly 4
must be maintained for full activation of NO syn-
thesis. They also indicate that an interaction impor-
tant for electron transfer occurs between the latch
region of CaM (formed by domains 1 and 3) and
an unknown region of nNOS that is distinct from
its CaM binding sequence [79]. The chimera studies
also revealed that signi¢cant CaM activation of
nNOS reductase domain electron transfer can occur
while triggering little or no heme reduction and NO
synthesis [44]. This indicates the processes are sepa-
rable, and that CaM must cause additional changes
beyond reductase domain activation to support a
normal rate of heme reduction and NO synthesis.
The NOSs display di¡erent a⁄nities toward CaM
with the general order being iNOSEeNOSs nNOS.
Recent work has begun to characterize the regions of
NOS involved in CaM binding. Full-length NOSs or
synthetic peptides that represent their canonical CaM
binding sequences have been used to determine CaM
binding and dissociation kinetics and derive a struc-
tural model [81^86]. Selective deletion of the CaM
binding sequence has also been investigated in
eNOS [88]. Whether CaM binds to the iNOS CaM
binding sequence in its Ca2-free form is controver-
sial [85,86]. In general, results using CaM binding
sequence peptides suggest that CaM a⁄nity towards
each NOS is largely determined by the canonical
sequence, with di¡erences arising presumably from
amino acid substitutions within the sequences. This
implies that the CaM response of each NOS could be
interchanged by simply swapping canonical binding
segments. However, such experiments indicate that at
least two other regions in NOS can modulate CaM
interaction. In iNOS an additional region essential
for high CaM a⁄nity is located in the reductase do-
main between the CaM binding sequence and the
FMN subdomain [68,87]. Based on sequence com-
parison this region is also present in the other NOS
but presumably in mutated form. A distinct structur-
al element that is present as an insertion in the re-
ductase domains of eNOS and nNOS but absent in
iNOS appears to negatively regulate CaM binding
[89]. This approx. 40 amino acid insert is located
within the FMN subdomain (Fig. 2) and is though
to be an autoinhibitory loop based on similar struc-
tures present in other CaM-responsive enzymes.
Studies that further characterize these potential con-
trol elements are awaited with interest.
3. Mechanism of NO synthesis from L-arginine
3.1. General features
The enzyme reaction mechanism is not completely
understood. The proposed mechanism of NO synthe-
sis (Fig. 5) draws parallels to cytochromes P-450
regarding a heme-based, stepwise activation of O2.
However, NOS must generate reactive oxygen at
two steps in the reaction, and evidence suggests
Fig. 2. Domain arrangement in rat nNOS. The enzyme consists
of an approx. 220 amino acid N-terminal leader sequence that
targets the enzyme in cells, a core oxygenase domain of approx.
500 amino acids which forms the active catalytic site, an ap-
prox. 30 amino acid CaM binding domain, and an approx. 700
amino acid reductase domain responsible for electron import
and transfer to the oxygenase domain. Sequence locations of
the N-terminal hairpin loop, heme-binding cysteine (C415), cav-
eolin binding consensus sequence, and putative CaM autoinhib-
itory loop are noted. The structural organization of iNOS and
eNOS are similar to nNOS except that they do not contain an
extensive leader sequence and the iNOS reductase domain is
missing the CaM autoinhibitory loop. For additional descrip-
tion see [33].
Fig. 1. Enzyme-catalyzed NO synthesis from L-arg. Hydroxyla-
tion of L-arg generates N-hydroxy-L-arg (NOHarg) as an inter-
mediate. The second step converts NOHarg to products NO
and citrulline.
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that distinct iron-oxygen species react in each step.
An electrophilic iron-oxo species (III) that is typi-
cally invoked in P-450 hydroxylation reactions is
thought to hydroxylate L-arg and form enzyme-
bound NOHarg. Next, the iron dioxy species (I)
formed by O2 binding to ferrous heme in the second
step is thought to act as an oxidant and abstract an
H atom or electron from NOHarg. This generates
the nucleophilic iron-peroxo species (II) that typi-
cally forms as an intermediate during cytochrome
P-450 oxygen activation. However, instead of the
O-O bond of (II) cleaving to form water and species
(III), the peroxo species (II) is predicted to react
directly with the NOHarg radical, generating a tetra-
hedral intermediate that rearranges to NO and citrul-
line. These issues are discussed in detail in reviews
[1,2].
3.2. Enzyme structural features that impact on NO
synthesis
Because NOS and cytochrome P-450s catalyze
similar chemistry, the crystal structures provide an
opportunity to examine similarities and di¡erences
in their respective heme environments that may
have important implications for mixed function oxy-
genase catalysis. For example, both enzymes have
hydrophobic distal pockets, although the NOS sub-
strate (L-arg) is much more hydrophilic than typical
P-450 substrates. This implies that hydrophobicity
may be more critical for proper O2 activation than
previously thought. The NOS distal pocket also lacks
obvious proton donating residues [36,37] that are
often present in P-450s to assist the O-O bond cleav-
age that converts iron-oxy species (II) to species (III).
L-Arg may be the proton donor that assists this crit-
ical cleavage during the ¢rst step in NO synthesis,
and thus may help catalyze its own hydroxylation
[37]. The lack of proton donors in the distal pocket
may be adventitious in the second step of NO syn-
thesis because it would prolong the lifetime of species
(II), allowing it to react with the NOHarg radical as
described above. On the proximal side of the NOS
heme, there is a conserved tryptophan (W199 in
Table 1
Mutagenesis of conserved cysteines in the NOS oxygenase domainsa
Mutationb Enzymec Comment
C109A miNOS, beNOS Lowers apparent a⁄nity toward H4B. Disrupts intersubunit disul¢de bridge
C194A miNOS, beNOS, rnNOS Heme-binding cysteine. Prevents heme incorporation
C211A hiNOS No apparent e¡ect
C222A hiNOS No apparent e¡ect
C284A hiNOS No apparent e¡ect
C378A hiNOS No apparent e¡ect
C451A hiNOS, miNOS, beNOS, rnNOS No apparent e¡ect
aReferences noted in text.
bNumbering follows the mouse iNOS sequence.
cNOS pre¢xes m, b, h, and r stand for mouse, bovine, human, and rat, respectively.
Fig. 3. Steps involved in assembly of an active iNOS dimer. See text for details. Adapted from [21].
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iNOS) that hydrogen bonds to the cysteine thiolate
which coordinates the heme iron [37]. This interac-
tion is not seen in cytochrome P-450s, and its func-
tion in NOS may be to reduce electron donation
from sulfur to the NOS heme iron, which would
fundamentally alter heme iron reactivity and also
stabilize species (II).
3.3. Catalytic roles for heme and H4B
Although the heme-based mechanism described
above is consistent with the NADPH stoichiometry
and other biochemical data [1,2], it does not explain
why H4B is required for NO synthesis. Recent work
has helped to clarify potential roles for heme and
H4B and together support the heme-catalyzed reac-
tion shown above. For example, O2 binding to the
heme of nNOS to form species (I) has now been
directly observed and the kinetics reported [90,91].
Also, certain cytochrome P-450s can catalyze NO
and urea formation from synthetic hydroxyguani-
dines or from NOHarg itself in the complete absence
of H4B [92]. The crystal structures of iNOS oxygen-
ase and a variety of biophysical studies show that L-
arg and related compounds are held close enough to
the heme iron to in£uence its electronic properties
and reactivity [77,93,94] and its binding of ligands
such as CO and NO [95^98]. In contrast, H4B is
held o¡ to the side of the heme and away from the
substrate [37], too distant to participate directly in
the oxygenation reactions. This leaves us to consider
that H4B may modulate oxy-heme reactivity. Indeed,
evidence that H4B markedly increases the reactivity
of the iron-dioxy species (I) has already been re-
ported [90]. H4B could modulate oxy-heme reactivity
through H-bonding interactions with a heme propi-
onate [37] or through less obvious electronic e¡ects.
Work that speci¢cally examined an electron donat-
ing function of H4B was done with nNOS in the
absence of NADPH [99]. Some conversion of L-arg
to NOHarg was observed and potentially attributed
to H4B-derived reducing equivalents, but the electron
involved was eventually found to derive from the
£avin semiquinone present in the nNOS reductase
domain [100]. The nNOS also exhibited a poor abil-
ity to reduce H2biopterin (H2B) or quininoid H2B to
H4B [101]. Characterization of iNOS containing a
series of H4B and H2B analogs con¢rmed that only
fully reduced tetrahydropteridines can support NO
synthesis [43]. This study also showed that it is the
structure of the aliphatic side-chain (6-dihydroxy-
propyl in H4B), rather than the redox state of the
pteridine ring, that primarily determines H4B binding
a⁄nity, the degree of heme iron spin shift, and the
ability to stabilize the enzyme ferrous-CO complex in
iNOS. Conversely, the redox state of the pteridine
ring was found to determine whether the pteridine
could support NO synthesis or stimulate iNOS to
increase its rate of NADPH consumption in response
to L-arg or related molecules. H2B and H4B sup-
ported a similar rate of NADPH-dependent heme
iron reduction in iNOS. The authors concluded
that the essential function of H4B must occur after
the iNOS heme iron becomes reduced and O2 binds
Fig. 5. Proposed mechanism of O2 activation and reactivity
during NO synthesis by NOS. See text for details. Adapted
from [2].
Fig. 4. Path of electron transfer in an iNOS dimer. The reduc-
tase domains each transfer NADPH-derived electrons to the
heme located in the adjacent subunit. Electron transfer between
reductase and oxygenase domains on the same subunit does not
occur. From [71].
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to form species (I), consistent with H4B modulating
oxy-heme reactivity [90].
3.4. Model systems and single-turnover studies
Because of the complexity of NO synthesis, groups
have begun to study single steps in the reaction and
examine the reactivity of discreet iron-oxy intermedi-
ates. The NOS and their oxygenase domains were
shown to catalyze conversion of NOHarg to citrul-
line and NO in a reaction that utilizes H2O2 as a
surrogate active oxygen donor [55,102,103]. H2O2 is
expected to bind to the ferric heme iron in NOS to
initially generate species (II) in Fig. 5, then undergo
O-O bond scission to form species (III). Although
these experiments were originally conducted to study
reaction of species (III) with L-arg in the ¢rst step of
NO synthesis, the results showed that L-arg was un-
reactive. Instead, NOHarg was converted to citrul-
line and nitrite plus nitrate and the system thus sup-
ports participation of the proposed nucleophilic iron-
peroxy species (II) in the second step. With nNOS
cyanoornithine was also formed during conversion of
NOHarg to citrulline [103]. Reactivity of NOHarg in
the H2O2-assisted system is consistent with earlier
chemical model studies that employed peracids
as nucleophilic oxidants of NOHguanidines, and
showed that they could generate urea and HNO
(detected as N2O) as products [1].
The reactivity of the nNOS iron dioxy species (I)
has been examined in a single turnover setting in
which the ferric heme of nNOS was provided only
with a single electron to generate species (I) [104].
Consistent with the mechanism in Fig. 5, species (I)
catalyzed stoichiometric conversion of NOHarg to
citrulline and NO (detected as nitrite), strongly sup-
porting a role for iron-dioxy species (I) as an initial
reactant in the second step of NO synthesis.
Although (I) was found incapable of catalyzing L-
arg hydroxylation in that same study, another group
investigating formation and reactivity of (I) at low
temperature (330‡C) found that (I) could generate
NOHarg from L-arg as well as convert NOHarg to
citrulline and NO [91]. They postulated that the sec-
ond electron required for L-arg hydroxylation might
come from bound H4B. However, the stoichiometry
of product formation (approx. 0.5 mol NOHarg
formed per mol of heme even in the presence of ex-
cess H4B) leaves open the possibility that heme-to-
heme electron transfer occurred within the time of
the reaction, which would enable half the heme irons
to catalyze a standard two-electron hydroxylation of
L-arg to NOHarg. Electron removal from bound
H4B would also require that the enzyme regenerate
reduced H4B for the next cycle, but H4B is buried
within the dimer interface [37] and cannot directly
interact with an external electron donor such as the
NOS reductase domain. In spite of these concerns,
electron donation from H4B remains an important
possibility that needs to be fully examined before
we can understand the mechanism of NO synthesis.
4. Control mechanisms and targeting
NOS activity is regulated by an impressive number
of post-translational mechanisms. Some modes of
regulation primarily involve a speci¢c NOS, while
others are shared between all NOSs. The following
brie£y summarizes a few of the most well docu-
mented mechanisms.
4.1. Feedback inhibition by NO
Because the NOSs are hemeproteins, their heme
irons can bind NO, and readily do so in their ferric
or ferrous states [97,105,106]. The association and
dissociation rate constants for iNOS NO complexes
are not greatly a¡ected by bound L-arg or H4B [96].
NO binding to the heme is important because it in-
hibits NOS catalysis in a reversible manner. NOS
ferric- or ferrous-NO complexes form within seconds
after NO synthesis is initiated [105,106]. The com-
plexes are inherently inactive and can rejoin the pro-
ductive catalytic cycle only after NO dissociates from
the heme iron. Dissociation rates are su⁄ciently slow
so that during steady-state catalysis in air-saturated
bu¡er 70^90% of iNOS and nNOS are present as
their inactive ferric- or ferrous-NO complexes, re-
spectively [105,106]. This partitioning forces the
NOS to operate at only a fraction of their true max-
imum activity during the steady state. Formation of
the iNOS-NO complex is dependent on the level of
NO in solution, and thus sensitive to NO scavengers,
whereas formation of the nNOS-NO complex ap-
pears to be independent of solution NO. In the pres-
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ence of su⁄cient L-arg and H4B, formation and
breakdown of the NOS-NO complex can occur
many times without irreversible loss of activity.
When NO complexes form during NOS catalysis,
the enzymes display a characteristic shift in their O2
response curves such that their rate of NO synthesis
becomes almost linearly proportional to the O2 con-
centration throughout the physiologic range [10,107].
This occurs because the NOS activity versus O2 re-
sponse curve under these conditions is primarily dic-
tated by the rate of NOS-NO complex breakdown,
which itself is a function of O2 concentration, and is
not dictated by the intrinsic a⁄nity of the NOS heme
iron for O2 [107]. Thus, the ‘inhibition’ brought on
by NO binding is actually a shift of the enzyme’s O2
response curve toward higher O2 concentrations.
Buildup of NOS-NO complexes during NO synthesis
in cells or tissues has not been directly investigated.
However, physiologic studies have already shown
that NOS activities in human or pig lung and cat
carotid body are proportional to a wide range of
O2 levels [108,109]. This implies that NOS-NO com-
plexes normally do form in these tissues and can
govern the O2 response of NOS, possibly enabling
the enzyme to function as an oxygen sensor. The
physiologic details of this hypothesis remain to be
investigated.
NO also inactivates NOS when its synthesis occurs
in the presence of sub-saturating H4B [1,2]. Under
this condition a gradual inactivation takes place
over several minutes, unlike the instant inhibition
attributed to heme-NO complex formation as dis-
cussed above. In at least one case the inhibited
NOS was reactivated by adding excess H4B [110].
Although the mechanism of inactivation has not
been directly investigated, it could involve uncoupled
O2 reduction that occurs in the absence of su⁄cient
H4B [50,51], dimer dissociation into monomers [21],
or NO binding to the heme and subsequent breakage
of the cysteine thiolate-heme iron bond, as occurs for
iNOS and nNOS treated with reagent NO in the
absence of H4B and L-arg [96,111]. This mode of
NOS inactivation could be important if cellular
H4B levels are limiting.
Finally, NO can also inhibit expression of iNOS
activity in cells by blocking assembly of the active
dimeric enzyme [112]. The mechanism appears to in-
volve NO blocking heme insertion into the iNOS
apoprotein. This occurs to such an extent that by
8 h post induction virtually all of the iNOS protein
being synthesized in cells accumulates as heme-free
monomers. Whether NO limits iNOS activity in ani-
mal tissues by this pathway needs to be examined.
4.2. Regulating NOS by H4B levels
H4B is a critical cofactor because it couples heme
iron reduction to NO synthesis, and is needed for
iNOS to dimerize in animal cells [21]. An unusual
aspect of H4B binding to NOS is that it is anticoop-
erative, that is, binding of the ¢rst H4B lowers the
enzyme’s a⁄nity for binding the second H4B by at
least an order of magnitude [59]. This raises the pos-
sibility that NOS could contain only one H4B per
dimer in some biological settings. In such cases, the
H4B-saturated subunit would generate NO while the
other H4B-free subunit would generate superoxide or
H2O2 [59]. This particularly pertains to nNOS, which
engages in a high rate of superoxide production in
the absence of H4B [59,113]. Although the biological
implications are not fully understood, an enzyme
generating NO and O2 simultaneously could conceiv-
ably form peroxynitrite. In cells induced to express
iNOS, genes encoding H4B biosynthetic enzymes are
also activated, insuring elevated H4B levels for dimer
assembly and coupled NO synthesis [114]. On the
other hand, resting cells or tissues expressing nNOS
or eNOS have variable levels of H4B, and there is
preliminary evidence that insu⁄cient H4B limits NO
synthesis in some settings [115,131].
4.3. Covalent modi¢cations of NOS
The eNOS has been reported to be myristoylated,
palmitoylated, farnesylated, acetylated, and phos-
phorylated all within its oxygenase domain (for re-
views, see [20,116,117]). These modi¢cations assist in
localizing the enzyme to cytosol, membrane compo-
nents, or organelles, and excepting phosphorylation,
may not signi¢cantly change the activity of the en-
zyme. When nNOS undergoes serine or tyrosine
phosphorylation in its oxygenase domain, this lowers
its activity almost two thirds by an unknown mech-
anism [118].
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4.4. Interactions between NOS and other proteins
A number of proteins that localize NOS to cellular
compartments and/or alter its catalytic activity have
been reported. The N-terminal approx. 220 amino
acid leader sequence unique to nNOS contains a
PDZ binding motif (Fig. 2) that interacts with sev-
eral proteins that may target the enzyme to signal
transduction hot spots within a cell [119,120]. The
biological consequences of this targeting are being
actively investigated. The nNOS leader sequence
also contains a binding site for a highly conserved
and widely expressed protein named PIN (protein
inhibitor of NO synthase, Fig. 2) [135], which when
bound to nNOS appears to destabilize its dimeric
structure [121].
The oxygenase domains of nNOS, eNOS, and
iNOS all contain binding motifs for caveolins (Fig.
2), which are a family of structural sca¡olding pro-
teins present in membrane caveoli. For nNOS, the
preferred interaction is with caveolin-3 [122]. Caveo-
lin-3 binds to nNOS and inhibits its NO synthesis
[122], the inhibition is reversed by CaM, and this
process is thought to locate nNOS near other signal
transduction proteins. The oxygenase domain of
eNOS contains a binding motif for caveolin-1, con-
sistent with this enzyme locating in caveolar mem-
branes in cells [123,124]. However, eNOS can also
interact with caveolin-3 [126].
Binding of caveolin-1 or its sca¡olding domain
peptide inhibits eNOS NO synthesis and some
work has been done to understand the mechanism
of inhibition. Although caveolin-1 does not interact
directly with CaM or the CaM binding motif on
eNOS, adding CaM can reverse the inhibition by
caveolin-1 in a competitive manner [124^128]. Muta-
genesis of the caveolin binding motif prevented in-
hibition of eNOS by caveolin-1, suggesting it does
indeed interact with this portion of the oxygenase
[126]. At this point, it is unknown how caveolin-1
inhibits and how CaM can reverse the inhibition. A
recent report shows that caveolin-1 interacts directly
with the eNOS reductase domain to inhibit its elec-
tron transfer function [129]. This suggests that cav-
eolins bind to multiple sites in the NOSs and may
prevent or slow electron transfer between the reduc-
tase and oxygenase domains. Antagonizing produc-
tive oxygenase-reductase domain interaction would
be consistent with the crystal structure of iNOS
that shows an analogous caveolin binding element
is located on a surface of the oxygenase near the
site postulated to dock the reductase domain for
electron transfer to the heme [37]. Interestingly, a
synthetic peptide representing a conserved neighbor-
ing region in the nNOS oxygenase domain inhibited
NADPH-dependent heme reduction in that enzyme
[113]. Further work on these issues is awaited with
interest.
The molecular chaperone HSP-90 has recently
been shown to increase the activity of eNOS two-
to three-fold [130]. This was demonstrated in a co-
expression system as well as with puri¢ed eNOS.
This is an important ¢nding because the speci¢c ac-
tivity of eNOS preparations have always been about
three- to ¢ve-fold lower than comparable iNOS or
nNOS preparations. How HSP-90 might increase
eNOS activity is still unclear, but one possibility is
that it may increase the rate of electron transfer be-
tween the reductase and oxygenase domains. Contin-
ued work along these lines is likely to identify many
cellular proteins that interact with the di¡erent NOS
isoforms to locate them at discreet sites in cells and
positively or negatively regulate their activity.
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